Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
- 30 November 2000
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 74 (5) , 255-259
- https://doi.org/10.1016/s0960-0760(00)00101-1
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with responseBreast Cancer Research and Treatment, 1998
- Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancerThe Lancet, 1995
- The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical studyEuropean Journal Of Cancer, 1994
- Estrogen and progesterone receptor concordance between primary and recurrent breast cancerJournal of Surgical Oncology, 1994
- Measurement of steroid hormone receptors in breast cancer patients on tamoxifenBreast Cancer Research and Treatment, 1993
- Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.Journal of Clinical Oncology, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Tamoxifen withdrawal response. Report of a caseArchives of internal medicine (1960), 1989
- CLINICAL SIGNIFICANCE OF TAMOXIFEN WITHDRAWAL RESPONSEThe Lancet, 1987